BCMA
41 programs · 39 companies
Programs
41
Companies
39
Active Trials
29
Targeting BCMA
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | NarcolepsyMDS | |
| ABB-8696 | AbbVie | Phase 3 | RSVHCC | |
| AZN-4015 | AstraZeneca | Preclinical | MCLCervical Ca | |
| REG-2328 | Regeneron | Phase 1 | Schizophrenia | |
| Adagratapinarof | Vertex Pharma | Preclinical | HSFabry | |
| BGN-6990 | BeiGene | Phase 2/3 | NarcolepsyCLL | |
| BGN-3305 | BeiGene | Phase 2 | Parkinson'sPsA | |
| ITC-1028 | Intra-Cellular | Phase 2 | FLHCC | |
| Pexanesiran | United Therapeutics | Phase 1 | NB | |
| Gozeosocimab | Illumina | Phase 2 | LNNB | |
| ACA-2691 | Acadia Pharma | Phase 3 | CF | |
| Elratuximab | Altimmune | Phase 3 | Cervical Ca | |
| Tezesertib | Cipla | Phase 1 | Alzheimer'sIgAN | |
| PEK-IIT-810 | Peking Univ Cancer Hosp | Phase 1/2 | NASH | |
| UCL-IIT-659 | UCLA Health | Approved | RB | |
| QUO-7972 | Quotient Ther | NDA/BLA | RettAtopic Derm | |
| IMV-6044 | Imvax | Phase 1/2 | Ewing SarcomaFL | |
| Tirasertib | Third Rock | Phase 1/2 | WilmsMG | |
| Motazasiran | Gelesis | Preclinical | HSACC | |
| Rilurapivir | Atea Pharma | NDA/BLA | NMOSD | |
| BLR-6474 | BioLineRx | Approved | ACCNMOSD | |
| PRI-9923 | Principia (Sanofi) | Phase 2/3 | Gastric CaCKD | |
| AMB-378 | Ambys Med | Phase 2 | NASHPsA | |
| Olpafutibatinib | Encoded Ther | Phase 3 | SCLCHNSCC | |
| SPA-7602 | Spark (Roche) | Preclinical | PSP | |
| Teraglumide | Genelux | Phase 2 | ADHDNarcolepsy | |
| 003-4903 | Boryung | Phase 3 | GBMMCC | |
| 4D-3071 | 4D Pharma | Approved | ALSRB | |
| KIA-5275 | Kiadis (Sanofi) | Phase 2/3 | Schizophrenia | |
| PHM-5291 | PharmaMar | Phase 3 | GISTRett | |
| NAN-6418 | Nordic Nano | Phase 2 | PNHAlzheimer's | |
| Pexainavolisib | BerGenBio | Approved | SMAFTD | |
| Voxainavolisib | Tolmar | Preclinical | SMASCD | |
| Tixasotorasib | ADC Therapeutics | Preclinical | IPFGA | |
| Elrabrutinib | Hyloris | Phase 3 | Endometrial Ca | |
| Kemazumab | JHL Biotech | Approved | NSCLC | |
| Suracagene | Divi's Laboratories | Phase 3 | Atopic DermEndometrial Ca | |
| Datoinavolisib | Cadila Healthcare | NDA/BLA | SchizophreniaPSP | |
| CAD-5301 | Cadila Healthcare | Phase 1/2 | ALLIPF | |
| Sototenlimab | Alkem Labs | Preclinical | PBC | |
| Semasertib | Dechra Pharma (EQT) | Phase 2/3 | MG |